Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

Johan Westin, Hans Nordlinder, Martin Lagging, +2

Journal of Hepatology

HepatologyAutoimmune DiseaseHepatitis CViral HepatitisLiver Physiology +12

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

Martin Lagging, Ana I. Romero, Johan Westin, +13

Hepatology

ImmunologyCovid-19Pretreatment Ip-10 AnalysisViral PersistenceViral Hepatitis +14

Interferon (IFN)–γ–Inducible Protein–10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN‐α2a and Ribavirin for Chronic Hepatitis C Virus Infection

Ana I. Romero, Martin Lagging, Johan Westin, +12

The Journal of Infectious Diseases

Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

Martin Lagging, Nina Langeland, Court Pedersen, +8

Hepatology

Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers

Sara Islam, Linda Antonsson, Johan Westin, +1

Scandinavian Journal of Gastroenterology

Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms

Martin Lagging, Galia Askarieh, Francesco Negro, +13

PLoS ONE

Systemic and Intrahepatic Interferon-Gamma-Inducible Protein 10 Kda Predicts the First-Phase Decline in Hepatitis C Virus Rna and Overall Viral Response to Therapy in Chronic Hepatitis C

Galia Askarieh, Åsa Alsiö, Paolo Pugnale, +11

Hepatology

Progression of fibrosis in untreated patients with hepatitis C virus infection

Martin Lagging, Johan Westin, Elisabeth Svensson, +5

Liver International

Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection

Johan Westin, Martin Lagging, Amar P. Dhillon, +10

Journal of Viral Hepatitis

Genotype 3HepatologyViral KineticsViral HepatitisLiver Physiology +12

Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial

Hans Orlent, Bettina E. Hansen, Marc Willems, +11

Journal of Hepatology

HepatologyHepatitis CViral HepatitisLiver PhysiologyPharmacology +9